{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:39Z","timestamp":1787003439661,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A massively enlarged kidney can impact quality of life of autosomal dominant polycystic kidney disease (ADPKD) patients. A recent in vitro study demonstrated that an allosteric modulator of the calcium sensing receptor decreases adenosine-3\u2032,5\u2032-cyclic monophosphate, an important factor for kidney enlargement in ADPKD. Therefore, the present study was performed to determine whether cinacalcet, a calcium sensing receptor agonist, suppresses kidney enlargement in hemodialysis patients with ADPKD. Alteration of total kidney volume together with clinical parameters was retrospectively examined in 12 hemodialysis patients with ADPKD treated at a single institution in Japan. In the non-cinacalcet group with longer hemodialysis duration (n\u2009=\u20095), total kidney volume had an annual increase of 4.19\u2009\u00b1\u20091.71% during an overall period of 877\u2009\u00b1\u2009494\u00a0days. In contrast, the annual rate of increase in total kidney volume in the cinacalcet group (n\u2009=\u20097) was significantly suppressed after cinacalcet treatment, from 3.26\u2009\u00b1\u20092.87% during a period of 734\u2009\u00b1\u2009352\u00a0days before the start of cinacalcet to \u2212\u20094.71\u2009\u00b1\u20096.42% during 918\u2009\u00b1\u2009524\u00a0days after initiation of treatment (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.047). The present findings showed that cinacalcet could be a novel therapeutic tool for suppression of kidney enlargement in hemodialysis patients with ADPKD.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-89480-1","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T06:09:20Z","timestamp":1620713360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Shinya","family":"Nakatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Nishide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senji","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijiro","family":"Kabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Machiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Uedono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeichi","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"89480_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres, V. E., Harris, P. C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287\u20131301. https:\/\/doi.org\/10.1016\/S0140-6736(07)60601-1 (2007).","journal-title":"Lancet"},{"key":"89480_CR2","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham, J. J. Clinical practice. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 359, 1477\u20131485. https:\/\/doi.org\/10.1056\/NEJMcp0804458 (2008).","journal-title":"N. Engl. J. Med."},{"key":"89480_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ki.2014.120","volume":"86","author":"EM Spithoven","year":"2014","unstructured":"Spithoven, E. M. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 86, 1244\u20131252. https:\/\/doi.org\/10.1038\/ki.2014.120 (2014).","journal-title":"Kidney Int."},{"key":"89480_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1053\/ajkd.2002.31407","volume":"39","author":"Y Ubara","year":"2002","unstructured":"Ubara, Y. et al. Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am. J. Kidney Dis. 39, 571\u2013579. https:\/\/doi.org\/10.1053\/ajkd.2002.31407 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"89480_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","volume":"71","author":"D Oberdhan","year":"2018","unstructured":"Oberdhan, D. et al. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. Am. J. Kidney Dis. 71, 225\u2013235. https:\/\/doi.org\/10.1053\/j.ajkd.2017.08.020 (2018).","journal-title":"Am. J. Kidney Dis."},{"key":"89480_CR6","doi-asserted-by":"publisher","first-page":"e0144526","DOI":"10.1371\/journal.pone.0144526","volume":"10","author":"H Kim","year":"2015","unstructured":"Kim, H. et al. Clinical correlates of mass effect in autosomal dominant polycystic kidney disease. PLoS ONE 10, e0144526. https:\/\/doi.org\/10.1371\/journal.pone.0144526 (2015).","journal-title":"PLoS ONE"},{"key":"89480_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12882-016-0434-0","volume":"18","author":"H Ryu","year":"2017","unstructured":"Ryu, H. et al. Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 18, 22. https:\/\/doi.org\/10.1186\/s12882-016-0434-0 (2017).","journal-title":"BMC Nephrol."},{"key":"89480_CR8","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/j.1523-1755.2004.00978.x","volume":"66","author":"LB Pupim","year":"2004","unstructured":"Pupim, L. B., Caglar, K., Hakim, R. M., Shyr, Y. & Ikizler, T. A. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int. 66, 2054\u20132060. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00978.x (2004).","journal-title":"Kidney Int."},{"key":"89480_CR9","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/ndt\/gfn167","volume":"23","author":"R de Mutsert","year":"2008","unstructured":"de Mutsert, R. et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol. Dial. Transplant. 23, 2957\u20132964. https:\/\/doi.org\/10.1093\/ndt\/gfn167 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"89480_CR10","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1172\/JCI64313","volume":"122","author":"K Hopp","year":"2012","unstructured":"Hopp, K. et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J. Clin. Investig. 122, 4257\u20134273. https:\/\/doi.org\/10.1172\/JCI64313 (2012).","journal-title":"J. Clin. Investig."},{"key":"89480_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/s0272-6386(97)90496-0","volume":"30","author":"T Yamaguchi","year":"1997","unstructured":"Yamaguchi, T., Nagao, S., Kasahara, M., Takahashi, H. & Grantham, J. J. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am. J. Kidney Dis. 30, 703\u2013709. https:\/\/doi.org\/10.1016\/s0272-6386(97)90496-0 (1997).","journal-title":"Am. J. Kidney Dis."},{"key":"89480_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone, V. H. 2nd., Wang, X., Harris, P. C. & Torres, V. E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323\u20131326. https:\/\/doi.org\/10.1038\/nm935 (2003).","journal-title":"Nat. Med."},{"key":"89480_CR13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/ki.2008.111","volume":"73","author":"PG Starremans","year":"2008","unstructured":"Starremans, P. G. et al. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5\u2019 end of Pkd1. Kidney Int. 73, 1394\u20131405. https:\/\/doi.org\/10.1038\/ki.2008.111 (2008).","journal-title":"Kidney Int."},{"key":"89480_CR14","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1681\/ASN.2006020136","volume":"17","author":"LA Smith","year":"2006","unstructured":"Smith, L. A. et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J. Am. Soc. Nephrol. 17, 2821\u20132831. https:\/\/doi.org\/10.1681\/ASN.2006020136 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89480_CR15","doi-asserted-by":"publisher","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif, G. A. et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl(-) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am. J. Physiol. Renal Physiol. 301, F1005-1013. https:\/\/doi.org\/10.1152\/ajprenal.00243.2011 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"89480_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1124\/jpet.114.213256","volume":"349","author":"M Aihara","year":"2014","unstructured":"Aihara, M. et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J. Pharmacol. Exp. Ther. 349, 258\u2013267. https:\/\/doi.org\/10.1124\/jpet.114.213256 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"89480_CR17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa1205511 (2012).","journal-title":"N. Engl. J. Med."},{"key":"89480_CR18","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930\u20131942. https:\/\/doi.org\/10.1056\/NEJMoa1710030 (2017).","journal-title":"N. Engl. J. Med."},{"key":"89480_CR19","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1073\/pnas.1301674110","volume":"110","author":"A Maeda","year":"2013","unstructured":"Maeda, A. et al. Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc. Natl. Acad. Sci. U.S.A. 110, 5864\u20135869. https:\/\/doi.org\/10.1073\/pnas.1301674110 (2013).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"89480_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"VE Torres","year":"2014","unstructured":"Torres, V. E. & Harris, P. C. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J. Am. Soc. Nephrol. 25, 18\u201332. https:\/\/doi.org\/10.1681\/ASN.2013040398 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89480_CR21","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth, E. F. et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U.S.A. 95, 4040\u20134045. https:\/\/doi.org\/10.1073\/pnas.95.7.4040 (1998).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"89480_CR22","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1038\/s41598-018-23732-5","volume":"8","author":"A Di Mise","year":"2018","unstructured":"Di Mise, A. et al. Activation of calcium-sensing receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells. Sci. Rep. 8, 5704. https:\/\/doi.org\/10.1038\/s41598-018-23732-5 (2018).","journal-title":"Sci. Rep."},{"key":"89480_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","volume":"12","author":"JSFDT Guideline Working Group","year":"2008","unstructured":"Guideline Working Group, J. S. F. D. T. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther. Apher. Dial. 12, 514\u2013525. https:\/\/doi.org\/10.1111\/j.1744-9987.2008.00648.x (2008).","journal-title":"Ther. Apher. Dial."},{"key":"89480_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1159\/000187586","volume":"65","author":"I Ishikawa","year":"1993","unstructured":"Ishikawa, I. & Saito, Y. Volume changes in autosomal dominant polycystic kidneys after the initiation of hemodialysis. Nephron 65, 649\u2013650. https:\/\/doi.org\/10.1159\/000187586 (1993).","journal-title":"Nephron"},{"key":"89480_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ndt\/gfv227","volume":"31","author":"Y Jung","year":"2016","unstructured":"Jung, Y. et al. Volume regression of native polycystic kidneys after renal transplantation. Nephrol. Dial. Transplant. 31, 73\u201379. https:\/\/doi.org\/10.1093\/ndt\/gfv227 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"89480_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","volume":"81","author":"EM Brown","year":"2001","unstructured":"Brown, E. M. & MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81, 239\u2013297. https:\/\/doi.org\/10.1152\/physrev.2001.81.1.239 (2001).","journal-title":"Physiol. Rev."},{"key":"89480_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1479-5876-9-201","volume":"9","author":"G Vezzoli","year":"2011","unstructured":"Vezzoli, G. et al. Calcium-sensing receptor and calcium kidney stones. J. Transl. Med. 9, 201. https:\/\/doi.org\/10.1186\/1479-5876-9-201 (2011).","journal-title":"J. Transl. Med."},{"key":"89480_CR28","doi-asserted-by":"publisher","first-page":"F611","DOI":"10.1152\/ajprenal.1998.274.3.F611","volume":"274","author":"D Riccardi","year":"1998","unstructured":"Riccardi, D. et al. Localization of the extracellular Ca2+\/polyvalent cation-sensing protein in rat kidney. Am. J. Physiol. 274, F611-622. https:\/\/doi.org\/10.1152\/ajprenal.1998.274.3.F611 (1998).","journal-title":"Am. J. Physiol."},{"key":"89480_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nrneph.2016.59","volume":"12","author":"D Riccardi","year":"2016","unstructured":"Riccardi, D. & Valenti, G. Localization and function of the renal calcium-sensing receptor. Nat. Rev. Nephrol. 12, 414\u2013425. https:\/\/doi.org\/10.1038\/nrneph.2016.59 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"89480_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 7, 1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001 (2017).","journal-title":"Kidney Int. Suppl."},{"key":"89480_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ki.2011.139","volume":"80","author":"NX Chen","year":"2011","unstructured":"Chen, N. X. et al. Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney Int. 80, 612\u2013619. https:\/\/doi.org\/10.1038\/ki.2011.139 (2011).","journal-title":"Kidney Int."},{"key":"89480_CR32","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1681\/ASN.2008090927","volume":"20","author":"VH Gattone 2nd","year":"2009","unstructured":"Gattone, V. H. 2nd. et al. Calcimimetic inhibits late-stage cyst growth in ADPKD. J. Am. Soc. Nephrol. 20, 1527\u20131532. https:\/\/doi.org\/10.1681\/ASN.2008090927 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89480_CR33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/ndt\/gfn527","volume":"24","author":"X Wang","year":"2009","unstructured":"Wang, X., Harris, P. C., Somlo, S., Batlle, D. & Torres, V. E. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrol. Dial.. Transplant. 24, 526\u2013534. https:\/\/doi.org\/10.1093\/ndt\/gfn527 (2009).","journal-title":"Nephrol. Dial.. Transplant."},{"key":"89480_CR34","doi-asserted-by":"publisher","first-page":"F1157","DOI":"10.1152\/ajprenal.00269.2012","volume":"303","author":"DK Atchison","year":"2012","unstructured":"Atchison, D. K., Harding, P., Cecilia Ortiz-Capisano, M., Peterson, E. L. & Beierwaltes, W. H. Parathyroid hormone stimulates juxtaglomerular cell cAMP accumulation without stimulating renin release. Am. J. Physiol. Renal Physiol. 303, F1157-1165. https:\/\/doi.org\/10.1152\/ajprenal.00269.2012 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"89480_CR35","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1038\/s41598-018-21397-8","volume":"8","author":"G Wang","year":"2018","unstructured":"Wang, G. et al. Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. Sci. Rep. 8, 3111. https:\/\/doi.org\/10.1038\/s41598-018-21397-8 (2018).","journal-title":"Sci. Rep."},{"key":"89480_CR36","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","volume":"19","author":"S Muto","year":"2015","unstructured":"Muto, S. et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin. Exp. Nephrol. 19, 867\u2013877. https:\/\/doi.org\/10.1007\/s10157-015-1086-2 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"89480_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5489\/cuaj.1338","volume":"7","author":"RH Breau","year":"2013","unstructured":"Breau, R. H. et al. A simple method to estimate renal volume from computed tomography. Can. Urol. Assoc. J. 7, 189\u2013192. https:\/\/doi.org\/10.5489\/cuaj.1338 (2013).","journal-title":"Can. Urol. Assoc. J."},{"key":"89480_CR38","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1074\/jbc.M009317200","volume":"276","author":"L Canaff","year":"2001","unstructured":"Canaff, L. et al. Extracellular calcium-sensing receptor is expressed in rat hepatocytes. Coupling to intracellular calcium mobilization and stimulation of bile flow. J. Biol. Chem. 276, 4070\u20134079. https:\/\/doi.org\/10.1074\/jbc.M009317200 (2001).","journal-title":"J. Biol. Chem."},{"key":"89480_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.molmed.2014.01.003","volume":"20","author":"ES Wills","year":"2014","unstructured":"Wills, E. S., Roepman, R. & Drenth, J. P. Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol. Med. 20, 261\u2013270. https:\/\/doi.org\/10.1016\/j.molmed.2014.01.003 (2014).","journal-title":"Trends Mol. Med."},{"key":"89480_CR40","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1136\/bmjopen-2019-032620","volume":"10","author":"J Griffiths","year":"2020","unstructured":"Griffiths, J., Mills, M. T. & Ong, A. C. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open 10, e032620. https:\/\/doi.org\/10.1136\/bmjopen-2019-032620 (2020).","journal-title":"BMJ Open"},{"key":"89480_CR41","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/ndt\/gfx186","volume":"32","author":"T Suwabe","year":"2017","unstructured":"Suwabe, T. et al. Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 32, 1176\u20131183. https:\/\/doi.org\/10.1093\/ndt\/gfx186 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"89480_CR42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1681\/ASN.2006070772","volume":"18","author":"M Inaba","year":"2007","unstructured":"Inaba, M. et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J. Am. Soc. Nephrol. 18, 896\u2013903. https:\/\/doi.org\/10.1681\/ASN.2006070772 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl 2","key":"89480_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1744-9987.12203","volume":"18","author":"H Shima","year":"2014","unstructured":"Shima, H. et al. Clinical experiences of bixalomer usage at our hospital. Ther. Apher. Dial. 18(Suppl 2), 13\u201318. https:\/\/doi.org\/10.1111\/1744-9987.12203 (2014).","journal-title":"Ther. Apher. Dial."},{"key":"89480_CR44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.semnephrol.2011.05.003","volume":"31","author":"AB Chapman","year":"2011","unstructured":"Chapman, A. B. & Wei, W. Imaging approaches to patients with polycystic kidney disease. Semin. Nephrol. 31, 237\u2013244. https:\/\/doi.org\/10.1016\/j.semnephrol.2011.05.003 (2011).","journal-title":"Semin. Nephrol."},{"key":"89480_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/RCT.0b013e318251db15","volume":"36","author":"S Soga","year":"2012","unstructured":"Soga, S. et al. Comprehensive comparative study of computed tomography-based estimates of split renal function for potential renal donors: modified ellipsoid method and other CT-based methods. J. Comput. Assist. Tomogr. 36, 323\u2013329. https:\/\/doi.org\/10.1097\/RCT.0b013e318251db15 (2012).","journal-title":"J. Comput. Assist. Tomogr."},{"key":"89480_CR46","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00261-003-0139-2","volume":"29","author":"EM Geraghty","year":"2004","unstructured":"Geraghty, E. M., Boone, J. M., McGahan, J. P. & Jain, K. Normal organ volume assessment from abdominal CT. Abdom Imaging 29, 482\u2013490. https:\/\/doi.org\/10.1007\/s00261-003-0139-2 (2004).","journal-title":"Abdom Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89480-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:14:44Z","timestamp":1670037284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89480-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89480"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89480-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"7 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10014"}}